Is STVN a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on The high-value solutions mix shift, with revenue (ttm) at ~EUR 1.20 billion (about ~$1.40 billion). The bear case rests on customer destocking has hit this company before and can again: after the May 2024 guidance cut on industry-wide vial destocking the shares fell ~22% in a single session, and several plaintiff firms opened investigations afterward (as of August 2026 no securities class action complaint with a case number appears to have been filed, so those remain investigations rather than litigation). Analysts covering it are spread from $20.00 to $32.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Customer destocking has hit this company before and can again: after the May 2024 guidance cut on industry-wide vial destocking the shares fell ~22% in a single session, and several plaintiff firms opened investigations afterward (as of August 2026 no securities class action complaint with a case number appears to have been filed, so those remain investigations rather than litigation). If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $20.00, -12.4% from the $22.84 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

The high-value solutions mix shift. Ready-to-use sterilized containers and integrated delivery systems reached ~45% of second-quarter 2026 revenue at ~EUR 135.9 million, growing ~16% against ~8% for the group. The most optimistic analyst target on STVN is $32.00, +40.1% from the $22.84 price. That figure is only reachable if this thesis works close to its best case.

Customer destocking has hit this company before and can again: after the May 2024 guidance cut on industry-wide vial destocking the shares fell ~22% in a single session, and several plaintiff firms opened investigations afterward (as of August 2026 no securities class action complaint with a case number appears to have been filed, so those remain investigations rather than litigation). Capital intensity is the near-term drag, with first-half 2026 capital expenditure of ~EUR 119.6 million, free cash flow of ~negative EUR 26.6 million and net debt of ~EUR 360.3 million, and full-year free cash flow guided only to a range of breakeven to ~EUR 20 million. Concentration cuts both ways, since ~22% to ~23% of revenue tied to GLP-1 therapies is a tailwind while the class is expanding and a single point of failure if pricing, supply or dosing formats change. Governance leaves outside holders with limited influence, because family control through Stevanato Holding S.r.l. plus enhanced voting rights means minority shareholders cannot force a change of direction. Finally, the reporting currency is the euro while the quote is in dollars, so a US holder absorbs the exchange rate on top of the operating result, and at roughly ~40 times trailing and ~30 times forward earnings the price already assumes the mix shift and the new plants deliver. The most pessimistic published target is $20.00, -12.4% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Stevanato Group is an Italian family-controlled maker of pharmaceutical glass vials, syringes and cartridges, plus pen injectors and packaging machinery.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (The high-value solutions mix shift) stalling in the reported numbers rather than in the narrative, the risk above (customer destocking has hit this company before and can again: after the May 2024 guidance cut on industry-wide vial destocking the shares fell ~22% in a single session, and several plaintiff firms opened investigations afterward (as of August 2026 no securities class action complaint with a case number appears to have been filed, so those remain investigations rather than litigation)) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

Containers and devices for injectable medicines. That covers glass vials, prefillable syringes and cartridges under the Ompi brand, sterilized ready-to-use EZ-fill formats, and the Alina pen injector platform. A separate Engineering segment builds the assembly, filling and visual inspection machinery that drug makers run on their own production lines.

Ordinary shares of Stevanato Group S.p.A. trade directly on the New York Stock Exchange under STVN, following the July 2021 initial public offering. No sponsored or unsponsored depositary receipt sits in between, and the company files with the SEC as a foreign private issuer, using Form 20-F annually and Form 6-K for quarterly results.

The company is headquartered in Piombino Dese, Italy, and keeps its books in euros, so revenue, margins and earnings per share all arrive in EUR even though the shares are quoted in USD. Second-quarter 2026 revenue of ~EUR 302.0 million and adjusted diluted EPS of ~EUR 0.14 are euro figures. Putting a dollar sign on them overstates or understates the result depending on the exchange rate that day.